Early safety and efficacy of APR-1051, a novel WEE1 inhibitor, in patients with cancer-associated gene alterations: Updated data from ACESOT-1051 phase 1 trial

APR-1051 - Aprea

Anthony Tolcher1; David Sommerhalder1; Shiraj Sen2; Crystal Miller3; David Stenehjem4; Mike Carleton3; Philippe Pultar3; Timothy Yap5

Oct 13, 2025